Réanimation

, Volume 21, Supplement 2, pp 399–405 | Cite as

Traitement du paludisme grave par artésunate intraveineux

Enseignement Supérieur en Réanimation Srlf / Spilf Médecin

Résumé

L’artésunate (AS), dérivé semi-synthétique de l’artémisinine, est un antipaludique très puissant. Dans le traitement du paludisme grave en zones d’endémie palustre, l’AS intraveineux (IV) est supérieur à la quinine (Q), tant chez l’adulte que chez l’enfant. En France, l’AS n’est disponible que depuis mai 2011, soumis à une autorisation temporaire d’utilisation (ATU). Cette mise au point retrace l’histoire de l’AS dans le monde, rapporte les principales études cliniques démontrant sa supériorité sur la Q, puis détaille l’utilisation de l’AS en France et en Europe, ainsi que les modalités pratiques de sa prescription et de sa surveillance. Abstract Artesunate, a semi-synthetic derivative of artemisinin, has proven to be an efficient therapy for severe malaria. In endemic areas, the findings clearly support the superiority of intravenous artesunate over quinine for the treatment of severe malaria in both adults and children. In France, artesunate is available since May 2011. This review describes the history of artesunate, reports the major studies supporting the superiority of artesunate over quinine, details the use of artesunate in France and Europe, and describes the prescription practices and monitoring of artesunate.

Mots clés

Artésunate Paludisme Plasmodium falciparum Réanimation Quinine 

Intravenous artesunate for the treatment of severe malaria

Keywords

Artesunate Malaria Plasmodium falciparum Intensive care Quinine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    World Health Organization (2010) World malaria report 2010. WHO, Geneva, http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf CrossRefGoogle Scholar
  2. 2.
    O’Meara WP, Mangeni JN, Steketee R, Greenwood B (2010) Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10:545–555PubMedCrossRefGoogle Scholar
  3. 3.
    Institut national de veille sanitaire, Centre national de référence du paludisme (2009) Rapport d’activitésGoogle Scholar
  4. 4.
    World Health Organization (2000) Severe falciparum malaria. Trans R Soc Trop Med Hyg 94(Suppl 1):1–90CrossRefGoogle Scholar
  5. 5.
    Société de pathologie infectieuse de langue française, Collège des universitaires de maladies infectieuses et tropicales, Société de réanimation de langue française, et al (2008) Recommandations for clinical practice. Management and prevention of imported Plasmodium falciparum malaria (Revision 2007 of the 1999 consensus conference). Med Mal Infect 38:39–117CrossRefGoogle Scholar
  6. 6.
    Bruneel F, Tubach F, Corne P, et al (2010) Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One 5(10):e13236PubMedCrossRefGoogle Scholar
  7. 7.
    Klayman DL (1985) Qinghaosu (artemisinin): an antimalarial drug from China. Science 228:1049–1055PubMedCrossRefGoogle Scholar
  8. 8.
    1994) Artemisinin. Trans R Soc Trop Med Hyg 88(Suppl 1):1–65Google Scholar
  9. 9.
    Brewer TG, Peggins JO, Grate SJ, et al (1994) Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 88(Suppl 1):33–36CrossRefGoogle Scholar
  10. 10.
    Wesche DL, DeCoster MA, Tortella FC, et al (1994) Neurotoxicity of artemisinin analogs in vitro. Antimicrob Agents Chemother 38:1813–1819PubMedCrossRefGoogle Scholar
  11. 11.
    Brewer TG, Grate SJ, Peggins JO, et al (1994) Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 51:251–259PubMedGoogle Scholar
  12. 12.
    Tran TH, Day NP, Nguyen HP, et al (1996) A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 335:76–83PubMedCrossRefGoogle Scholar
  13. 13.
    van Hensbroek MB, Onyiorah E, Jaffar S, et al (1996) A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 335:69–75PubMedCrossRefGoogle Scholar
  14. 14.
    Artemether-Quinine Meta-analysis Study Group (2001) Trans R Soc Trop Med Hyg 95:637–650CrossRefGoogle Scholar
  15. 15.
    Eastman RT, Fidock DA (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7:864–874PubMedGoogle Scholar
  16. 16.
    Buffet PA, Safeukui I, Deplaine G, et al (2011) The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117:381–392PubMedCrossRefGoogle Scholar
  17. 17.
    Dondorp A, Nosten F, Stepniewska K, et al (2005) Artesunate versus quinine for treatment of severe Falciparum malaria: a randomised trial. Lancet 366:717–725PubMedCrossRefGoogle Scholar
  18. 18.
    World Health Organization (2006) Guidelines for the treatment of malaria. WHO, Geneva, http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf Google Scholar
  19. 19.
    Lalloo DG, Shingadia D, Pasvol G, et al (2007) UK malaria treatment guidelines. J Infect 54:111–121PubMedCrossRefGoogle Scholar
  20. 20.
    Dondorp AM, Fanello CI, Hendriksen IC, et al (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376:1647–1657PubMedCrossRefGoogle Scholar
  21. 21.
    Sinclair D, Donegan S, Lalloo DG (2011) Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev (3): CD005967Google Scholar
  22. 22.
    Zoller T, Junghanss T, Kapaun A, et al (2011) Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 17:771–777PubMedCrossRefGoogle Scholar
  23. 23.
    Teuscher F, Gatton ML, Chen N, et al (2010) Artemisinininduced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 202:1362–1368PubMedCrossRefGoogle Scholar
  24. 24.
    Morch K, Strand O, Dunlop O, et al (2008) Severe malaria and artesunate treatment, Norway. Emerg Infect Dis 14:1816–1818PubMedCrossRefGoogle Scholar
  25. 25.
    Bartoloni A, Tomasoni L, Bartalesi F, et al (2010) Combined intravenous treatment with artesunate and quinine for severe malaria in Italy. Am J Trop Med Hyg 83:274–276PubMedCrossRefGoogle Scholar
  26. 26.
    Mali S, Steele S, Slutsker L, et al (2010) Malaria surveillance-United States, 2008. MMWR Surveill Summ 59:1–15PubMedGoogle Scholar
  27. 27.
    Watts G (2011) Use artesunate not quinine to treat severe malaria, say experts. BMJ 342:d2590. doi: 10.1136/bmj.d2590PubMedCrossRefGoogle Scholar
  28. 28.
    Dondorp AM, Nosten F, Yi P, et al (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467PubMedCrossRefGoogle Scholar
  29. 29.
    Dondorp AM (2011) Interscience conference on antimicrobial agents and chemotherapy, communication orale, ChicagoGoogle Scholar

Copyright information

© Société de réanimation de langue française (SRLF) and Springer-Verlag France 2011

Authors and Affiliations

  1. 1.Service de réanimation médicochirurgicale, centre hospitalier de Versailleshôpital André-MignotLe ChesnayFrance

Personalised recommendations